• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2018-2019 年美国和欧洲新型药物的治疗价值评估。

Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019.

机构信息

Institute of Law, University of Zurich, Zurich, Switzerland.

Program on Regulation, Therapeutics, and Law, Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

出版信息

JAMA Netw Open. 2022 Apr 1;5(4):e226479. doi: 10.1001/jamanetworkopen.2022.6479.

DOI:10.1001/jamanetworkopen.2022.6479
PMID:35385091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8987900/
Abstract

This economic evaluation study assesses the clinical benefit of novel drugs approved in 2018 and 2019 and examines whether drugs approved with special regulatory designations appear to provide meaningful therapeutic value.

摘要

本经济评价研究评估了 2018 年和 2019 年批准的新药的临床获益，并考察了具有特殊监管地位批准的药物是否具有有意义的治疗价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c3/8987900/0c70927902d9/jamanetwopen-e226479-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c3/8987900/0c70927902d9/jamanetwopen-e226479-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93c3/8987900/0c70927902d9/jamanetwopen-e226479-g001.jpg

相似文献

1
Therapeutic Value Assessments of Novel Medicines in the US and Europe, 2018-2019.2018-2019 年美国和欧洲新型药物的治疗价值评估。
JAMA Netw Open. 2022 Apr 1;5(4):e226479. doi: 10.1001/jamanetworkopen.2022.6479.
2
Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.具有不确定治疗价值的癌症药物的批准：欧洲和美国的监管决策比较。
Milbank Q. 2020 Dec;98(4):1219-1256. doi: 10.1111/1468-0009.12476. Epub 2020 Oct 6.
3
Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.患者尽早获得药物：卫生技术评估机构需要跟上新的上市许可方法。
Public Health Genomics. 2016;19(3):187-91. doi: 10.1159/000446537. Epub 2016 Jun 1.
4
Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.尽管人们对 FDA 的审查程序提出了批评，但新的癌症药物在美国上市的速度比在欧洲更快。
Health Aff (Millwood). 2011 Jul;30(7):1375-81. doi: 10.1377/hlthaff.2011.0231. Epub 2011 Jun 16.
5
Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration.欧洲药品管理局、加拿大卫生部和美国食品药品监督管理局的监管数据透明度。
J Law Med Ethics. 2021;49(3):456-485. doi: 10.1017/jme.2021.67.
6
Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?为低收入国家注册药品：世界卫生组织、美国食品和药物管理局以及欧洲药品管理局严格的审查程序有多合适？
Trop Med Int Health. 2014 Jan;19(1):23-36. doi: 10.1111/tmi.12201. Epub 2013 Oct 17.
7
Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study.评估美国药品相互批准立法对新型疗法可及性的潜在临床影响：一项队列研究。
BMJ Open. 2017 Feb 8;7(2):e014582. doi: 10.1136/bmjopen-2016-014582.
8
European Medicines Agency: Approval of new glucose-lowering medicines for type 2 diabetes.欧洲药品管理局：2型糖尿病新型降糖药物的批准
Diabetes Obes Metab. 2018 Sep;20(9):2057-2058. doi: 10.1111/dom.13360. Epub 2018 Jun 5.
9
The European Medicines Agency and Publication of Clinical Study Reports: A Challenge for the US FDA.欧洲药品管理局与临床研究报告的发布：对美国食品药品监督管理局的一项挑战
JAMA. 2017 Mar 7;317(9):905-906. doi: 10.1001/jama.2017.0918.
10
Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan.日本、美国和欧洲对日本首次批准的新药在监管审查中延迟和差异的理由。
Br J Clin Pharmacol. 2021 Aug;87(8):3279-3291. doi: 10.1111/bcp.14749. Epub 2021 Mar 5.

引用本文的文献

1
How was published evidence used in model-based cost - utility analysis for lung cancer?已发表的证据如何用于肺癌的基于模型的成本效益分析？
Health Econ Rev. 2025 Jun 16;15(1):50. doi: 10.1186/s13561-025-00651-6.
2
'We need to be part of the solution': lessons from the 2024 PPRI Conference on ensuring access to affordable medicines through innovative policies.“我们需要成为解决方案的一部分”：2024年药品价格监管指数（PPRI）会议关于通过创新政策确保可及负担得起药品的经验教训
J Pharm Policy Pract. 2024 Dec 24;17(Suppl 1):2442002. doi: 10.1080/20523211.2024.2442002. eCollection 2024.
3
Expedited Approval of Urgently Needed Drugs in China.

本文引用的文献

1
Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway: The Need for Reforms.履行美国食品药品监督管理局加速批准途径的使命：改革的必要性。
JAMA Intern Med. 2021 Oct 1;181(10):1275-1276. doi: 10.1001/jamainternmed.2021.4604.
2
Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study.FDA 和 EMA 加速审批计划与新药的治疗价值之间的关联：回顾性队列研究。
BMJ. 2020 Oct 7;371:m3434. doi: 10.1136/bmj.m3434.
3
Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs.
中国急需药品的加速审批
JAMA Health Forum. 2025 Jan 3;6(1):e244750. doi: 10.1001/jamahealthforum.2024.4750.
4
Defining 'therapeutic value' of medicines: a scoping review.定义药品的“治疗价值”：范围综述。
BMJ Open. 2023 Dec 18;13(12):e078134. doi: 10.1136/bmjopen-2023-078134.
5
Approval and therapeutic value of gene therapies in the US and Europe.美国和欧洲基因治疗的审批和治疗价值。
Gene Ther. 2023 Nov;30(10-11):756-760. doi: 10.1038/s41434-023-00402-4. Epub 2023 Nov 8.
6
Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort study.美国和欧洲（2011-20 年）药物一线与二线适应证的治疗价值：回顾性队列研究。
BMJ. 2023 Jul 5;382:e074166. doi: 10.1136/bmj-2022-074166.
7
Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.2007 年至 2021 年美国和欧洲加速批准或有条件上市药物的治疗价值。
JAMA Health Forum. 2022 Aug 5;3(8):e222685. doi: 10.1001/jamahealthforum.2022.2685.
8
Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments.肿瘤学试验设计的意义以及疗效-安全性数据的不确定性对卫生技术评估的影响。
Curr Oncol. 2022 Aug 16;29(8):5774-5791. doi: 10.3390/curroncol29080455.
9
A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.增加新药研发和分配的价值和公平性的提案。
Int J Health Serv. 2022 Jul;52(3):363-371. doi: 10.1177/00207314221100647. Epub 2022 May 12.
评估美国食品药品监督管理局（FDA）替代终点表格中所包含的替代指标背后的证据，以支持癌症药物的批准。
EClinicalMedicine. 2020 Apr 13;21:100332. doi: 10.1016/j.eclinm.2020.100332. eCollection 2020 Apr.
4
Reforming the Orphan Drug Act for the 21st Century.为21世纪改革《孤儿药法案》。
N Engl J Med. 2019 Jul 11;381(2):106-108. doi: 10.1056/NEJMp1902943.